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Background. We and others have reported that patients experiencing their first episode of psychosis already have
significant structural brain abnormalities. Antipsychotics seem to reverse subcortical volume deficits after months of
treatment. However, the early impact of medication on brain morphology is not known.
Method. Forty-eight individuals in their first episode of psychosis underwent magnetic resonance imaging (MRI)
brain scanning. Twenty-six were antipsychotic naive and 22 were newly treated with antipsychotic medication for
a median period of 3 weeks. In each group, 80% of subjects received a diagnosis of schizophrenia. The two groups
were balanced for age, sex, handedness, ethnicity, height, years of education, paternal socio-economic status (SES)
and Positive and Negative Syndrome Scale (PANSS) score. Group differences in whole-brain grey matter were
compared voxel by voxel, using Brain Activation and Morphological Mapping (BAMM) software. We also conducted
testing of group differences with region-of-interest (ROI) measurements of the caudate nucleus.
Results. Relative to the untreated group, those receiving antipsychotic medication for 3–4 weeks had significantly
greater grey-matter volumes in the bilateral caudate and cingulate gyri, extending to the left medial frontal gyrus.
ROI analysis confirmed that, in treated patients, the right and left caudate nuclei were significantly larger by 10%
(p<0.039, two-tailed) and 9% (p<0.048, two-tailed) respectively.
Conclusions. Early striatal grey-matter enlargement may occur within the first 3–4 weeks of antipsychotic treatment.
Possible reasons for putative striatal hypertrophy and its implications are discussed.
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Introduction
Brain imaging studies have generally shown that
patients with schizophrenia have smaller global and
regional brain volumes compared to typically de-
veloping individuals (Harrison, 1999 ; Shenton et al.
2001 ; Jayakumar et al. 2006 ; Chua et al. 2007). Smaller
cortical size has been demonstrated in the prefrontal,
entorhinal and anterior cingulate cortices (Harrison,
1999 ; Tamminga et al. 2000). By contrast, enlargement
of subcortical regions after antipsychotic treatment
has also been demonstrated (Chakos et al. 1994).
Never-medicated patients have smaller caudate
nuclei, putamen and nucleus accumbens (Gur et al.
1998 ; Corson et al. 1999 ; Dazzan et al. 2004 ; Girgis et al.
2006 ; Chua et al. 2007), the size of which increases
following months of typical antipsychotic treatment
(Gur et al. 1998; Corson et al. 1999) and may be partly
explained by increased striatal blood flow (Corson
et al. 2002). The phenomenon is regarded as evidence
of antipsychotic-induced hypertrophy (Gur et al.
1998).
This raises the question of whether treatment-
related changes hold clues to the pathophysiology.
Antipsychotic drugs markedly reduce symptoms
within the first 3 weeks of treatment (Johnstone
et al. 1978), even as early as week 2, with 68% of
the improvement at 1 year achieved within the first
month (Leucht et al. 2005). Aberrant development of
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prefrontal–striatal circuitry during adolescence is
thought to be related to the pathophysiology of schizo-
phrenia (Laruelle, 2000). According to the dopamine
hypothesis of schizophrenia, an excess of dopamine
in this brain system is associated with psychosis
(Carlsson, 1978) and antipsychotic drugs that block
dopamine receptors are able to oppose this, a process
referred to as ‘endogenous dopamine sensitization’
(Laruelle, 2000).
Forty years after antipsychotic medication rev-
olutionized the therapeutic armory against schizo-
phrenia, the reason why there is a time lag before
antipsychotic drug treatment takes effect (Johnstone
et al. 1978) remains obscure. It may be partly explained
by the time taken for an interaction between dopamine
receptors and antipsychotics to alter gene expression,
leading to neurogenesis and synaptic changes
(Konradi & Heckers, 2001). It has been suggested that
the clinical lag period coincides with the time course
of an underlying neural response to treatment (Leucht
et al. 2005).
Neuroplastic modulation of the caudate nucleus,
part of the dopamine-rich striatum, is supported by a
volumetric increase after 3 (Massana et al. 2005) to 18
months of antipsychotic treatment (Chakos et al. 1994).
However, after shorter periods of treatment, this effect
may be less marked. For example, increases in grey
matter were reported in the superior temporal gyrus
and middle temporal gyrus, but not the basal ganglia,
after 15 antipsychotic-naive patients underwent 6
weeks of treatment with the atypical antipsychotic
risperidone (Girgis et al. 2006). Another study of 13
patients suffering a relapse of schizophrenia found
no effects on the basal ganglia, despite a diffuse volu-
metric increase throughout the cortex after 4 weeks
of treatment with second-generation atypical anti-
psychotics, but not with haloperidol (Garver et al.
2005). Conceivably, the caudate nuclear volume in-
crease was not demonstrated because of weak study
power. An alternative explanation is that the effect
depends upon the duration of exposure to anti-
psychotics.
To address this issue, we conducted a pilot study
of 22 patients newly diagnosed with schizophrenia
scanned for a median period of 3 weeks after start-
ing antipsychotic medication for the first time and
26 control patients also newly diagnosed with schizo-
phrenic but never medicated. A voxel-by-voxel
whole-brain grey-matter volumetric comparison
(voxel-based morphometry, VBM) of the two patient
groups enabled the early effects of antipsychotic
treatment in first-episode schizophrenia to be evalu-
ated. In addition, a region-of-interest (ROI) measure-
ment of the caudate nuclei was undertaken. An
important aspect of this study was its naturalistic
design for medication selection, in that the choice of
antipsychotic did not conform to a fixed protocol but
instead was an entirely clinician-led decision.
Method
Subjects
All patients presenting to the hospital with psychosis
were screened for eligibility to join the study. In-
clusion criteria were : age 18–50 years ; no previous
history of any antipsychotic medication; and first ex-
perience of psychotic symptoms (i.e. hallucinations
and/or delusions and/or thought disorder, with de-
cline in daily functioning) according to DSM-IV (APA,
1994) confirmed by two independent specialists in
psychiatry. Duration of psychosis was assessed using
the Interview for the Retrospective Assessment of
Schizophrenia (IRAOS; Hafner et al. 1992) and has
been described in detail elsewhere (Chen et al. 2005).
Exclusion criteria were : any history of neurological
problems; loss of consciousness ; persistent head-
aches ; head trauma; electroconvulsive therapy; psy-
chostimulant use ; and special school attendance. The
study received the approval of the Institutional Re-
view Board of the hospital concerned. All subjects
were Chinese. Patients were screened within the first
day of presenting to hospital and all gave full in-
formed written consent to participate according to the
Declaration of Helsinki. These patients were part of a
larger brain imaging project of first-episode psychosis
patients to evaluate brain morphology compared to
typically developing matched controls (results avail-
able in Chua et al. 2007). The Positive and Negative
Syndrome Scale (PANSS; Kay et al. 1987) was used to
assess patients’ psychopathology when they presented
to hospital. The antipsychotic-treated group received a
magnetic resonance imaging (MRI) brain scan 3 weeks
after antipsychotic treatment had started. The anti-
psychotic-naive group had an MRI brain scan just be-
fore antipsychotic treatment was initiated.
MRI data acquisition
Patients were scanned on a GE Signa 1.5 T system
(General Electric, Milwaukee, WI, USA) in Queen
Mary Hospital, Hong Kong. The scan lasted for 20
minutes. A consultant radiologist (K.S.T.), blind to di-
agnosis, reviewed each MRI scan for any gross ano-
maly. Scans aligned to the AC–PC line were acquired
across the whole brain as follows. PD/T2 sequence :
dual-echo fast spin–echo data sets with TR 5–6 s,
anterior–posterior direction 0.86 mm, right–left direc-
tion 1.15 mm, slice direction 3 mm, matrix size
256r192, contiguous, phase inversion time 10 ms, two
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echoes with TE=20/80 ms, number of excitations=1,
echo train length=8. PD/T2 scans were used for
computerized VBM analysis. T1 sequence : fast SPGR
3D oblique scans with 128 slices, contiguous, 1.2 mm
thick, Nex=1, TR 11.4 s, TE 4.2 ms, flip angle 15x, FOV
24r24, matrix 25r256. T1 scans were used for man-
ual (ROI) tracing.
Preprocessing and analysis
Group differences in grey matter were mapped using
Brain Activation and Morphological Mapping
(BAMM) software version 2.5 (www.bmu.psychiatry.
cam.ac.uk/BAMM/index.html) on a SPARC work-
station (Sun Microsystems Europe Inc., Surrey, UK)
as described previously (Sigmundsson et al. 2001 ;
McAlonan et al. 2002, 2005 ; Chua et al. 2007). In brief,
PD/T2 images were processed to remove extra-
cerebral tissues (Suckling et al. 1999a) and then seg-
mented into grey and white matter, cerebrospinal
fluid (CSF), dura and other non-cerebral tissues, which
were subsequently ignored (Suckling et al. 1999b).
The segmented images were mapped into the stan-
dard space of Talairach and Tournoux (Talairach &
Tournoux, 1988) by affine transformation of each
proton density image to a group-specific template
(Suckling et al. 1999b ; McAlonan et al. 2005 ; Chua et al.
2007), applying the derived mappings to the tissue
maps and followed by smoothing with a 4.4 mm
Gaussian kernel. The effect of diagnostic group was
estimated at each voxel by regression of a general lin-
ear model to the estimates of grey and white matter
occupancy separately. Maps of the corresponding
standardized coefficient were subject to an inference
procedure in which the significance of three-
dimensional cluster statistics was assessed using non-
parametric (permutation) methods (Bullmore et al.
1999). The statistical thresholds were corrected for
multiple comparisons by setting the p value such that
<1 false positive cluster was expected in each map
under the null hypothesis (Suckling & Bullmore,
2004).
ROI analysis
Caudate and lateral ventricular volumes were evalu-
ated using the T1 dataset as described previously
(Murphy et al. 1992 ; Chua et al. 2007). One indepen-
dent operator who was blind to the groups aligned the
axial scans along the AC–PC line using MEASURE
software (Barta et al. 1997). Left and right caudate
nuclei were traced according to standard anatomical
boundaries. Volumes were calculated by multiplying
the summed pixel cross-sectional areas by slice thick-
ness. As all measurements were performed blind by a
single operator, only the intra-class correlation coef-
ficient (ICC) was calculated.
Results
Demographic and clinical comparison of groups
In total, 50 first-episode psychotic patients were re-
cruited for the study; of these, two patients declined
the MRI scan. Of the 48 patients who underwent MRI
brain scanning, 22 were antipsychotic medicated and
26 antipsychotic naive. However, the scans for three
patients had movement artefacts and were not sui-
table for further processing. Thus, the final num-
bers for image analysis were 20 antipsychotic-treated
and 25 antipsychotic-naive patients. Two independent
clinicians gave the diagnosis of schizophrenia to 16
(80%) of the antipsychotic-treated and 21 (84%) of the
antipsychotic-naive patients ; for the remaining four
patients in each group, diagnoses of acute and transi-
ent psychosis or schizophreniform psychosis were
given. The diagnoses were also confirmed by the re-
sponsible clinician upon case-note review, 6 months
after presentation. Antipsychotic medication pre-
scribed followed a naturalistic approach, that is it was
entirely clinician led according to local practice. The
treated group received either typical (haloperidol in 13
patients, trifluoperazine in one patient, and sulpiride
in one patient) or atypical medication (amisulpride in
five patients). Both groups were balanced for age, sex,
handedness, ethnicity, paternal socio-economic status
(SES) and height (see Table 1).
Brain morphological differences
Grey-matter volume differences
In the antipsychotic-treated group, compared to the
antipsychotic-naive patient group, significant clusters
of volume excess in cerebral grey matter were detected
after 3–4 weeks of antipsychotic treatment, involving
bilateral regions of the caudate, putamen, anterior
cingulate and medial prefrontal cortex (see Fig. 1 and
Table 2). When the analysis was restricted to subjects
with schizophrenia, the results did not change sig-
nificantly.
ROI measurements
We used ROI planimetry to trace the caudate nuclei
of the striatum. The ICC of the rater was 0.94 for both
left and right caudate on 10 scans performed 1 month
apart. In patients treated for a median of 3 weeks, the
left caudate was larger by 9% (two-tailed p<0.048)
and the right caudate by 10% (two-tailed p<0.039)
(see Fig. 2 and Table 3). When the analysis was
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restricted to subjects with schizophrenia, the anti-
psychotic-treated group also had significantly larger
left and right caudate nuclei by 10.7% on each side
(independent t test, p<0.03, one-tailed).
Discussion
We report that discrete brain morphological differ-
ences related to antipsychotic treatment occur as early
as 3 weeks post-exposure. In particular, we have
demonstrated for the first time that the caudate
nucleus appears enlarged in patients who have
undergone just a few weeks of antipsychotic treat-
ment for first-episode schizophrenia. In this study
of 48 patients, we found that, compared to the anti-
psychotic-naive patient group, the antipsychotic-
treated group had significantly greater grey-matter
volumes in the bilateral caudate nuclei and cingulate
gyri, extending to the left medial frontal gyrus.
ROI analysis confirmed larger striatal volumes in the
treated group of the order of 9–10% in both caudate
nuclei.
The present finding has an intriguing symmetry
with our previous work showing that caudate volumes
are as much as 11% smaller in untreated patients
with first-episode schizophrenia when compared to
matched healthy volunteers (Chua et al. 2007). This
indicates that caudate volume might be ‘normalized’
or increased after antipsychotic drug administration in
the very early weeks of treatment. We did not attempt
to correlate caudate volumes with PANSS ratings be-
cause the latter were performed at first presentation,
whereas the brain scan was conducted at two time-
points (i.e. at presentation or 3 weeks after drug
treatment). The groups did not differ significantly on
baseline PANSS ratings, yet after 3 weeks of treatment
caudate volumes were significantly greater than those
–16 –12 –8 –4 –1
+4 +8 +12 +16 +20
Fig. 1. Grey-matter differences in the antipsychotic-naive
(n=25) and antipsychotic-treated groups (n=20). The blue
colour represents regions where grey-matter volumes were
significantly greater in the antipsychotic-treated group
compared to the antipsychotic-naive group. The right side of
the brain corresponds to the right side of the figure. The
z coordinate for each axial slice in standard Talairach and
Tournoux space is given in millimetres. Statistical threshold
is p<0.002 corrected.
Table 1. Characteristics of all patients with psychosis (n=45)
Variable
Antipsychotic-treated
group (n=20)
Antipsychotic-naive
group (n=25)
Age (years), mean (S.D.) 29 (8.6) 32 (9.5)
Sex, % males 50 40
Handedness, % right-handed 90 76
Education (years), mean (S.D.) 12 (2.9) 10 (1.3)
Height (cm), mean (S.D.) 162 (10) 159 (8.7)
Parental SES, mean (S.D.) 3.8 (1.4) 4.2 (1.6)
PANSS score, mean 78 (23) 68 (16)
Antipsychotic CPZ equivalent
(mg), mean (S.D.)
318 (245) 0
Duration of untreated psychosis
(days)
Mean (S.D.) 286 (356) 353 (547)
Median 90 105
Range 6–1095 16–2008
Antipsychotic duration (days)
Mean (S.D.) 27 (21) 0
Median 22
Range 5–86
SES, Socio-economic status ; PANSS, Positive and Negative Syndrome Scale ;
CPZ, chlorpromazine ; S.D., standard deviation.
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never treated. It is now known that the antipsychotic
effect may take place as early as week 2 (Leucht et al.
2005), and even manifest as early as some hours post-
intramuscular antipsychotic, without being due to
simple reduction in agitation (Agid et al. 2008). Con-
ceivably, treatment effectiveness may depend on
‘rewiring’ neuronal circuitry (Konradi & Heckers,
2001), and would partly account for the time needed
for clinical efficacy. The mechanism by which anti-
psychotic drugs cause hypertrophy of the caudate
nucleus (Chakos et al. 1994 ; Shenton et al. 2001) and
possibly also of the putamen and thalamus (Gur et al.
1998) remains to be fully elucidated. However, it has
already been shown that antipsychotic drugs can lead
to genetic modulation of neuronal function in the
striatum or prefrontal cortex (Weinberger & Lipska,
1995), the putative sites of action of typical and atypi-
cal antipsychotic drugs (Pilowsky, 2001). We were in-
trigued that our treated group had grey-matter excess
in the medial frontal and cingulate gyri because these
regions are implicated in behavioural monitoring and
error detection (Rushworth et al. 2007). Animal studies
have shown that dopamine blockade with olanzapine
(Wang et al. 2004) or haloperidol (Kippin et al. 2005)
can stimulate new cell proliferation and therefore,
taken together, the data support neuroplastic change
in the fronto-limbic circuitry in the early phase of drug
treatment.
The coincidence of structural abnormality and anti-
psychotic target in psychosis adds to the evidence
that effective medication modifies those prefrontal-
temporolimbic cortical networks most vulnerable to
progressive tissue loss in the first 5 years after illness
onset (Thompson et al. 2001). Although others have
Table 2. Grey-matter differences in the antipsychotic-naive (n=25) and antipsychotic-treated groups (n=20) (p<0.002 corrected)a
Brain region
Talairach coordinates (mm)
Cluster size
(voxels)
Brodmann
area (BA)x y z
L cingulate gyrus, extending
to L medial frontal, L caudate nucleus
x0.6 21.8 5.1 593 BA 0, BA 24
R cingulate gyrus, extending
to R caudate nucleus
4.9 21.2 4 93 BA 0, BA 24
L, Left ; R, right.
a A sample Talairach coordinate (x, y, z) is given for the approximate centre of each three-dimensional (3D) cluster but,
as shown in Fig. 1, the 3D cluster is not confined to this area alone.
Table 3. Region-of-interest analysis of the caudate nuclei
Brain region
Volume (ml), mean (S.D.)
Group
difference (%)
Independent t test
Antipsychotic-treated
group (n=20)
Antipsychotic-naive
group (n=25) t value p value
L caudate 4.20 (0.50) 3.86 (0.68) 9 2.035 0.048*
R caudate 4.17 (0.57) 3.80 (0.62) 10 2.129 0.039*
L, Left ; R, right ; S.D., standard deviation.
* Two-tailed significance, p<0.005.
Antipsychotic-treated
(n = 20)
Antipsychotic-naive
(n = 25)
4.25
4.00
3.75
3.50
95
%
 C
I
L caudate
R caudate
Fig. 2. Caudate volume differences between
antipsychotic-treated and antipsychotic-naive groups.
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shown that antipsychotic medication may increase
caudate size (Chakos et al. 1994 ; Shenton et al. 2001),
placed with our previous findings of smaller caudate
volume in first-episode schizophrenia (Chua et al.
2007), we suggest that this constitutes a ‘reversal ’ of
pathology as early as 3 weeks into treatment. We pre-
viously proposed that reduced caudate volumes might
provide a useful biomarker for psychosis and it has
been argued that the excess of dopamine in patients
with schizophrenia has a toxic effect on neurons,
potentially inducing an increase in oxidative stress
(Keshavan, 1999). The results of the present study lead
us to extend our proposal and we speculate that nor-
malized caudate volumes early in treatment might
mirror the clinical response.
However, there is controversy in the field. Although
patients with first-episode psychosis have been shown
to have reduced caudate volumes in many recent
MRI studies (Harrison, 1999 ; Shenton et al. 2001 ;
Jayakumar et al. 2006 ; Chua et al. 2007), others have
reported no changes in caudate volume (Crespo-
Facorro et al. 2006). The question of whether patients
were already medicated, however briefly, on entry to
each study is a salient point, as is the type of medi-
cation administered. Girgis et al. (2006) reported no
increase in caudate nucleus volume despite increases
in various cortical regions following risperidone
treatment. In our study the medication patients re-
ceived was entirely clinician led: 2/3 received typical
antipsychotics and 1/3 were treated with atypical
antipsychotics reflecting the changes in treatment
guidelines over time. Differences in the effect of typical
and atypical antipsychotic medication on neuropla-
sia have been observed previously and discussed
(McClure et al. 2006). In ongoing work, first-episode
patients are usually treated with atypical anti-
psychotics, therefore we plan to repeat the present
study in these patients.
A limitation of our study was the use of two separ-
ate patient groups. This design does not allow for the
exclusion of a possible confound of inherent group
differences. A longitudinal study of a single cohort of
patients, each serving as their own control, would be
the optimal to unequivocally demonstrate drug treat-
ment effects on brain morphology and is currently in
progress. The results presented here motivate further
research into antipsychotic drug actions in patients
with first-episode schizophrenia early in the course
of treatment and sharpen a focus on the precise
mechanisms by which medication may increase grey-
matter volume and thereby reduce symptoms of psy-
chosis.
In conclusion, our data indicate that greater striatal
volumes in patients treated with antipsychotic drugs
compared to never-treated patients are present after
just 3 weeks. This extends our previous report of
striatal deficits in untreated patients with first-episode
psychosis (Chua et al. 2007). We propose that, in ad-
dition to acting as a useful disease marker (Chua et al.
2007), caudate nuclear volume may represent a useful
indicator of early recovery in schizophrenia.
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